Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614102 | 0.81 | MEN1 (0.57) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL3755094 | 0.81 | MEP1B (0.49) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL1019456 | 0.80 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10CYP2C9PTGDR2 | |
| SCHEMBL3922786 | 0.80 | LMNA (0.62) | ALDH1A1LMNAMEN1KMT2AVCAM1 | |
| SCHEMBL10979724 | 0.80 | ALDH1A1 (0.49) | ALDH1A1LMNAMEN1KMT2AVCAM1 | |
| SCHEMBL12225750 | 0.80 | ALDH1A1 (0.58) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL2538476 | 0.80 | LMNA (0.54) | ALDH1A1LMNAHSD17B10KMT2AWDR5 | |
| SCHEMBL25678233 | 0.79 | ALDH1A1 (0.54) | ALDH1A1LMNAHSD17B10KMT2AWDR5 | |
| SCHEMBL3054739 | 0.78 | ALDH1A1 (0.65) | ALDH1A1LMNAKMT2ACYP2C9CA9 | |
| SCHEMBL1279551 | 0.78 | LMNA (0.46) | ALDH1A1LMNAHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | ALDH1A1 3391/4885LMNA 3914/4885HSD17B10 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.